Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
{{output}}
Background: In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), targets neutrop... ...
